Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361353 | 0.95 | GBA1 (0.43) | CNR2GBA1NAAAEPHX2 | |
| SCHEMBL2361579 | 0.95 | GBA1 (0.43) | CNR2GBA1NAAAEPHX2 | |
| SCHEMBL13455823 | 0.93 | GBA1 (0.46) | CNR2GBA1NAAAEPHX2 | |
| SCHEMBL13954685 | 0.93 | GBA1 (0.46) | CNR2GBA1NAAAEPHX2 | |
| SCHEMBL14119588 | 0.93 | GBA1 (0.46) | CNR2GBA1NAAAEPHX2 | |
| SCHEMBL2448811 | 0.89 | CNR2 (0.33) | CNR2NAAA | |
| SCHEMBL17384324 | 0.89 | GBA1 (0.38) | GBA1EPHX2TSHRPPP5C | |
| SCHEMBL8970189 | 0.89 | GBA1 (0.38) | GBA1EPHX2TSHRPPP5C | |
| SCHEMBL17384323 | 0.89 | GBA1 (0.38) | GBA1EPHX2TSHRPPP5C | |
| SCHEMBL8970146 | 0.83 | GBA1 (0.46) | GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | CNR2 82/4885GBA1 590/4885NAAA 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.